Skip to main content

Amy Claudine Hobeika, PhD

Assistant Professor in Surgery
Office: 404A MSRB 1, Research Dr, Durham, NC 27710
Campus Mail: DUMC Box 2606 Med Ctr, Durham, NC 27710

Education and Training

  • Post doctoral Associate, University of Florida, 1997 - 1999
  • Teaching Assistant, University of Florida, 1993 - 1996
  • Laboratory Technician, University of Florida, 1993 - 1996
  • Ph.D., University of Florida, 1997

Publications

Sun, Baodong, Michael D. Kulis, Sarah P. Young, Amy C. Hobeika, Songtao Li, Andrew Bird, Haoyue Zhang, et al. “Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease.” Mol Ther 18, no. 2 (February 2010): 353–60. https://doi.org/10.1038/mt.2009.195.

Full Text

Osada, T., D. Hsu, S. Hammond, A. Hobeika, G. Devi, T. M. Clay, H. K. Lyerly, and M. A. Morse. “Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.” Br J Cancer 102, no. 1 (January 5, 2010): 124–33. https://doi.org/10.1038/sj.bjc.6605364.

Full Text

Morse, Michael A., Amy C. Hobeika, Takuya Osada, Delila Serra, Donna Niedzwiecki, H Kim Lyerly, and Timothy M. Clay. “Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.” Blood 112, no. 3 (August 1, 2008): 610–18. https://doi.org/10.1182/blood-2008-01-135319.

Full Text

Hobeika, Ac, T. Osada, D. Serra, S. Peplinski, K. Hanson, Y. Tanaka, D. Niedzwiecki, et al. “Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.” Cytotherapy 10, no. 3 (January 2008): 289–302. https://doi.org/10.1080/14653240801927040.

Full Text

Morse, Michael, Lee Langer, Alexander Starodub, Amy Hobeika, Timothy Clay, and H Kim Lyerly. “Current immunotherapeutic strategies in colon cancer.” Surg Oncol Clin N Am 16, no. 4 (October 2007): 873–x. https://doi.org/10.1016/j.soc.2007.07.005.

Full Text

Morse, Michael A., Amy Hobeika, Takuya Osada, Donna Niedzwiecki, Paul Kelly Marcom, Kimberly L. Blackwell, Carey Anders, Gayathri R. Devi, H Kim Lyerly, and Timothy M. Clay. “Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.” J Transl Med 5 (September 6, 2007): 42. https://doi.org/10.1186/1479-5876-5-42.

Full Text

Johnson, Benjamin F., Timothy M. Clay, Amy C. Hobeika, H Kim Lyerly, and Michael A. Morse. “Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.” Expert Opin Biol Ther 7, no. 4 (April 2007): 449–60. https://doi.org/10.1517/14712598.7.4.449.

Full Text

Hobeika, A. C., T. M. Clay, and M. A. Morse. “Monitoring immunity to cancer vaccines.” Enhancer  Biotherapy of Cancer, December 4, 2006.

Scholars@Duke

Osada, Takuya, Timothy Clay, Amy Hobeika, H Kim Lyerly, and Michael A. Morse. “NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.” Cancer Immunol Immunother 55, no. 9 (September 2006): 1122–31. https://doi.org/10.1007/s00262-005-0089-3.

Full Text

Pages